BACK

A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who are ineligible for, intolerant to, or have progressed on previous trastuzumab deruxtecan treatment (EmpowHER 303)